State Street Corp Buys 28,251 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

State Street Corp increased its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 2.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,163,754 shares of the company’s stock after buying an additional 28,251 shares during the period. State Street Corp’s holdings in Health Catalyst were worth $9,473,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Quest Partners LLC purchased a new position in shares of Health Catalyst in the 3rd quarter worth $34,000. Quarry LP grew its stake in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the 3rd quarter valued at about $59,000. Mackenzie Financial Corp bought a new position in shares of Health Catalyst in the 2nd quarter worth approximately $70,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Health Catalyst in the third quarter worth approximately $84,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on HCAT. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. JPMorgan Chase & Co. upped their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Finally, Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.79.

Insider Transactions at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now directly owns 72,250 shares in the company, valued at $601,120. This represents a 21.05 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now directly owns 98,702 shares in the company, valued at approximately $777,771.76. This trade represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,551 shares of company stock worth $532,105. 2.50% of the stock is currently owned by insiders.

Health Catalyst Trading Up 2.8 %

Shares of NASDAQ HCAT opened at $7.09 on Friday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business’s 50 day moving average is $7.99 and its two-hundred day moving average is $7.46. The stock has a market capitalization of $431.41 million, a P/E ratio of -5.25 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) EPS. As a group, research analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.